IP
Innate Pharma S.A.
IPHA · NASDAQ
$1.90 +0.53% (+$0.01)
1M -15.93%
Market Cap 156.3M €
P/E Ratio -
Div. Yield -
ROE 933.18%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 56.07x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Rev. growth 63.58%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 100.00%
Net margin 1,764.51%
Op. margin 1,916.94%
Quality
1 /100
Poor ROIC 153.27%
ROE 933.18%
ROA 78.44%
Debt
24 /100
High Current ratio 1.27x
Int. coverage -110.77x
Debt/Equity N/A
Stability
28 /100
Unstable Beta 0.88x
Rev. volatility 38.58%
EPS volatility 364.59%
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o IPHA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jonathan E. Dickinson
Employees
163
Headquarters
Marseille